Lukotas HD Tablet SR is a combination pharmaceutical formulation containing Ambroxol 75mg, Levocetirizine 5mg, and Montelukast 10mg, designed to provide comprehensive management of respiratory conditions characterized by cough, allergic rhinitis, and bronchial asthma. Ambroxol, a mucolytic agent, facilitates the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency and easing expectoration. Levocetirizine, a potent non-sedating antihistamine, effectively alleviates symptoms of allergic rhinitis such as sneezing, nasal congestion, and itching by selectively inhibiting peripheral H1 histamine receptors. Montelukast, a leukotriene receptor antagonist, helps in preventing bronchoconstriction and inflammation associated with asthma and allergic rhinitis by blocking cysteinyl leukotriene receptors in the airways. The sustained-release (SR) formulation ensures prolonged therapeutic action, enhancing patient compliance by reducing dosing frequency. Lukotas HD Tablet SR is indicated for the symptomatic relief of cough with mucus, allergic rhinitis, and asthma management, particularly in patients requiring simultaneous control of mucus hypersecretion, allergic symptoms, and leukotriene-mediated inflammation. It should be used under medical supervision, considering potential contraindications and drug interactions. Adverse effects are generally mild but may include headache, gastrointestinal discomfort, or drowsiness.